Bright Minds Biosciences Inc.
NASDAQ:DRUGBiotechnology
+$0.62 today
- Market cap
- $204.78M
- Beta
- -0.11
- P/E (TTM)
- -29.8
- EPS (TTM)
- -$2.87
Volume 0.14M
Average 0.27M
DRUG Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Bright Minds Biosciences Inc.NASDAQ: DRUG
Selling, General & Admin · Q2 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of CA$2.23M rose 229.7% year over year, ahead of the +147.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 104.7% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of CA$0 (-100.0%) for the fiscal year ending Sep 2026, a slowdown from the +77.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$2.23M+104.7% QoQ
- Last fiscal yearSep 2025
- CA$2.57M+77.5% YoY
- LTMMar 2026
- CA$4.67M+147.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +229.7% | -100.0% | -329.7 pp |
| 1 year | +77.5% | -100.0% | -177.5 pp |
| 3-year CAGR | +0.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
CAD · from the income statement
- Latest · FY2025
- 2.57M CAD
- Year-over-year change
- +77.5%
- 4-year CAGR
- +2.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 2.57M | +77.5% |
| FY2024 | 2024-09-30 | 1.45M | -34.3% |
| FY2023 | 2023-09-30 | 2.2M | -13.8% |
| FY2022 | 2022-09-30 | 2.55M | +10.5% |
| FY2021 | 2021-09-30 | 2.31M | — |
Selling, General & Admin vs competitors
How DRUG compares with its peers on the latest reported figures
No competitor Selling, General & Admin figures are available to compare.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.31M | 12.18M | 5M | 1.18M | 11.08M |
| Selling, General & Admin | 2.31M | 2.55M | 2.2M | 1.45M | 2.57M |
| Operating Expenses | 8.62M | 14.98M | 7.39M | 2.82M | 13.94M |
| Depreciation & Amortization | 8.62M | 6.04K | 72.45K | 73.36K | 76.87K |
| EBITDA | (27.64K) | (14.96M) | (7.3M) | (2.73M) | (12.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.62M) | (14.98M) | (7.39M) | (2.82M) | (13.94M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 30.13K | 1.52M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (27.64K) | 10.15K | 14.19K | 20.82K | 1.71M |
| Income Before Tax | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.74) | (6.15) | (1.98) | (0.65) | (1.78) |
| EPS (Diluted) | (4.74) | (6.15) | (1.98) | (0.65) | (1.78) |
| Weighted Avg Shares | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M |
| Weighted Avg Shares (Diluted) | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M |
Bright Minds Biosciences Inc.
NASDAQ:DRUG
Intrinsic Alpha fair value
Locked
Current Price
$20.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.